Melatonin, Honestly

Melatonin is the rare sleep product with a real mechanism and a real evidence base — for a narrow job. It is a timing signal, not a sedative: it tells the body clock when night is, and it works best when the problem is a timing problem. This page separates the circadian science from the marketing, and explains why timing beats dose.

Melatonin Is a Timing Signal, Not a Sedative

The pineal gland releases melatonin when the retina reports darkness, and the body clock reads that nightly rise as "night." That is the whole job: melatonin does not push sleep the way a GABA drug does — it tells the clock when to schedule the sleep window. The practical consequence is that melatonin is at its best for timing problems: delayed sleep phase, jet lag, shift-work transitions, and the slow drift toward later nights. For a person who is tired at the right time but cannot fall asleep, melatonin is often the wrong tool — that is a conditioned-arousal problem, which the When Sleep Won't Come topic addresses behaviorally.

• 🕰️ It marks the phase — the nightly rise in melatonin (DLMO) is the clock's signature; shifting it shifts the whole sleep window.
• 🌅 Light is the bigger hand — morning light is the dominant clock-setter; melatonin is a fine-tuning knob next to it, which is why the morning light dosing page pairs with this one.

What the Circadian Trials Show

The phase-response studies are the cleanest evidence in the field. Give melatonin in the evening and the body clock moves earlier; give it in the morning and the clock drifts later — the same direction-dependence seen with light (Lewy et al., 1992). The surprise is how little melatonin it takes. In patients with delayed sleep phase, 0.3 mg advanced the clock more than 3 mg did, and both shifted sleep earlier (Mundey et al., Sleep, 2005). In healthy adults, 0.5 mg and 3 mg produced nearly parallel phase-response curves (Burgess et al., JCEM, 2010). The message: the signal matters more than the strength.

• 🌙 Evening advances, morning delays — take it in the evening to move the sleep window earlier; the morning dose pushes the clock the wrong way.
• 🧭 Jet lag is the classic use — the Cochrane review found melatonin helpful when timed to the destination's bedtime (Herxheimer & Petrie, 2002).
• 🧪 Small effect on plain insomnia — roughly seven minutes faster sleep onset on average is real but modest; it is not the same class of effect as behavioral treatment.

The Dose Question: More Is Not Automatically Better

The dosing instinct — if 3 mg is good, 10 mg is better — runs straight into the data. The sleep-onset benefit in meta-analysis came from studies mostly using 2–3 mg or less, and the phase-shift studies found low doses at least as effective. Higher doses add side effects without adding effect: next-morning grogginess, vivid dreams, headache, and a body-temperature dip are the usual reports. The honest summary: the dose-response curve for sleep looks flat beyond a few milligrams, and the curve for side effects does not.

• 📉 Flat benefit, rising cost — nothing in the published record shows 10 mg beating the studied range.
• 😵 The hangover is dose-shaped — grogginess and vivid dreams cluster at higher doses, and morning blood levels stay higher longer.

The Timing Question

Timing is where melatonin is won or lost. For a phase advance — going to bed earlier — the research doses land roughly two to three hours before the target bedtime, in the window when the clock is most receptive to the advance signal. For jet lag, the Cochrane-tested pattern is to take it at the destination's local bedtime. The same dose at the wrong hour does nothing useful or pushes the clock the wrong way — "take melatonin before bed" is the least useful sentence in the supplement aisle. The circadian rhythm topic owns the fuller clock map.

• ⏰ Evening window, not bedtime — for most people the window is 1–3 hours before the desired sleep time, not at lights-out.
• ✈️ Jet lag: destination time rules — eastward travel is the classic fit; westward is often better served by light.
• 🔁 Consistency beats precision — the same time nightly, with morning light anchoring the other end, does more than a perfectly timed dose.

What's Actually in the Bottle

Supplements are regulated as foods in the US, not drugs, and the label is a claim more than a specification. The most-cited audit of commercial melatonin products (Erland & Saxena, Journal of Clinical Sleep Medicine, 2017) measured actual content ranging from roughly 83% below the label claim to nearly five times above it — and detected serotonin in over a quarter of products. That variability is the category, not a corner-store problem. Third-party testing seals (USP, NSF) narrow the gap but do not change the regulatory frame, which the Sleep Protocol series treats as a standing caution.

• 🔬 Content varies by a factor of five — the same bottle, same lot, different measured dose; treat the front label as approximate.
• 🧪 Serotonin is the surprise contaminant — relevant for anyone on antidepressants; the interaction question belongs in the pharmacist's inbox.
• 🏷️ Seals are worth something — third-party testing at least verifies content and purity; it does not verify effectiveness.

Who Should Ask Before Using It

Melatonin's short-term record is good — but "safe enough" does not survive every body. Pregnancy and breastfeeding: there is no adequate safety data, so the question goes to the obstetric clinician. Children: use has spread fast while pediatric safety research lags, and the pediatric reviews flag the gap sharply (Kennaway, Journal of Paediatrics and Child Health, 2015). And melatonin measurably lowers blood pressure in people with hypertension in a small controlled trial (Scheer et al., Hypertension, 2004) — a reminder that a hormone with cardiovascular effects deserves the same respect as any medication.

• 🤰 Pregnancy and breastfeeding — insufficient safety data; the conversation belongs with the clinician, not the supplement aisle.
• 🧒 Children and teens — pediatric dosing is an active research question; the pediatric reviews ask for clinician involvement.
• ❤️ Blood pressure and medications — melatonin interacts with antihypertensives, warfarin, and some antidepressants; the pharmacist should see the list.
• 🫘 Liver and kidney disease — melatonin is cleared through liver enzymes and its metabolites through the kidney; chronic disease changes the math.

Practical Rules for a Melatonin Trial

If a clinician has cleared the way, the evidence points to a short, low-dose, timed experiment rather than a nightly habit:

• ⬇️ Start at the low end — 0.3–1 mg, not the 5–10 mg the shelf suggests; the studied circadian range is the honest range.
• 🕗 Take it in the advance window — roughly 1–3 hours before the target bedtime, same time nightly, morning light anchoring the other end.
• 📓 Time-box the trial — two to three weeks with a sleep diary; if the timing problem has not budged, more melatonin is not the answer.

Questions, Answered Briefly

• ❓ Can melatonin help if my problem is falling asleep, not timing? The average benefit is small — about seven minutes — so for plain onset trouble the behavioral toolkit is the bigger lever.
• ❓ Is 10 mg dangerous? Short-term use is generally well tolerated, but the extra milligrams buy side effects without buying sleep; high doses are a clinician question, not a shelf decision.
• ❓ Why does the same dose work one night and not the next? Melatonin's job is phase, and phase is slow — a few nights of correct timing beat any single night's dose.
• ❓ What about timed-release products? They prolong melatonin's presence through the night, suiting some people's sleep maintenance — but the phase-shift evidence is built on immediate-release forms; another clinician-pharmacist conversation.

Related Topics